Lujin Wu

2.1k total citations · 1 hit paper
17 papers, 1.5k citations indexed

About

Lujin Wu is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Biochemistry. According to data from OpenAlex, Lujin Wu has authored 17 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Cardiology and Cardiovascular Medicine and 6 papers in Biochemistry. Recurrent topics in Lujin Wu's work include Eicosanoids and Hypertension Pharmacology (6 papers), Peroxisome Proliferator-Activated Receptors (5 papers) and Cardiovascular Function and Risk Factors (3 papers). Lujin Wu is often cited by papers focused on Eicosanoids and Hypertension Pharmacology (6 papers), Peroxisome Proliferator-Activated Receptors (5 papers) and Cardiovascular Function and Risk Factors (3 papers). Lujin Wu collaborates with scholars based in China, United States and Poland. Lujin Wu's co-authors include Dao Wen Wang, Wen Zheng, Chen Chen, Lingli Dong, Jiong Hu, Bei Wang, Ingrid Fleming, Jing Chen, Jiali Nie and Bei Wang and has published in prestigious journals such as Circulation Research, Scientific Reports and Hypertension.

In The Last Decade

Lujin Wu

16 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets

2021 839 citations Bei Wang, Lujin Wu et al. Signal Transduction and Targeted Therapy profile →

Peers

Countries citing papers authored by Lujin Wu

Since Specialization

Citations

This map shows the geographic impact of Lujin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lujin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lujin Wu more than expected).

Fields of papers citing papers by Lujin Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lujin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lujin Wu. The network helps show where Lujin Wu may publish in the future.

Co-authorship network of co-authors of Lujin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Lujin Wu. A scholar is included among the top collaborators of Lujin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lujin Wu. Lujin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Unleashing the Potential of Nrf2: A Novel Therapeutic Target for Pulmonary Vascular Remodeling 2023 ·Antioxidants ·Qin Fang, (unknown), Shuiqing Hu, Jie Ding, Lei Liu, (unknown), (unknown), Lujin Wu, Xiaoquan Rao, Yan Wang	0
2	Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target 2022 ·Frontiers in Cardiovascular Medicine ·(unknown), Jie Ding, (unknown), Lei Liu, Qing Fang, Dao Wen Wang, Lujin Wu, Yan Wang	13
3	Focus on Autoimmune Myocarditis in Graves' Disease: A Case-Based Review 2021 ·Frontiers in Cardiovascular Medicine ·Lujin Wu, Wei Wang, (unknown), (unknown), Ning Zhou, Yan Wang, Dao Wen Wang	9
4	Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets breakdown → 2021 ·Signal Transduction and Targeted Therapy ·Bei Wang, Lujin Wu, Jing Chen, Lingli Dong, Chen Chen, Wen Zheng, Jiong Hu, Ingrid Fleming, Dao Wen Wang	839
5	Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK 2021 ·Frontiers in Pharmacology ·Hongyang Shu, Weijian Hang, (unknown), Jiali Nie, Lujin Wu, Wenjun Zhang, Dao Wen Wang, Ning Zhou	26
6	NLRX1 knockout aggravates lipopolysaccharide (LPS)-induced heart injury and attenuates the anti-LPS cardioprotective effect of CYP2J2/11,12-EET by enhancing activation of NF-κB and NLRP3 inflammasome 2020 ·European Journal of Pharmacology ·Gang Zhao, Xiaoting Wang, (unknown), (unknown), Jianfeng Li, Lujin Wu, Rongfu Xu, Jinxiang Han, Haitao Yuan	15
7	PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1 2020 ·Frontiers in Pharmacology ·Wei Wang, Qin Fang, Zhihao Zhang, Dao Wen Wang, Lujin Wu, Yan Wang	17
8	Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review 2020 ·Journal of Clinical Pharmacy and Therapeutics ·(unknown), Wei Wang, Yan Wang, Lujin Wu	7
9	PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis 2019 ·BMC Cancer ·Lujin Wu, Wei Wang, (unknown), Huihui Li, Chen Chen, Dao Wen Wang	18
10	The immune-metabolic regulatory roles of epoxyeicosatrienoic acids on macrophages phenotypic plasticity in obesity-related insulin resistance 2018 ·Prostaglandins & Other Lipid Mediators ·(unknown), Lujin Wu, Ling Tu, Xizhen Xu, Dao Wen Wang	4
11	Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway 2018 ·Aging Cell ·Lujin Wu, Ke Wang, Wei Wang, Wen Zheng, Peihua Wang, Lei Liu, Dao Wen Wang	83
12	Ranolazine prevents pressure overload‐induced cardiac hypertrophy and heart failure by restoring aberrant Na⁺ and Ca²⁺ handling 2018 ·Journal of Cellular Physiology ·Jiali Nie, Quanlu Duan, Mengying He, (unknown), Bei Wang, Chi Zhou, Lujin Wu, Wen Zheng, Chen Chen, Dao Wu Wang, Katherina M. Alsina, Xander H.T. Wehrens, Dao Wen Wang, Li Ni	49
13	CYP2J2 and Its Metabolites EETs Attenuate Insulin Resistance via Regulating Macrophage Polarization in Adipose Tissue 2017 ·Scientific Reports ·(unknown), Lujin Wu, Peihua Wang, Wen Zheng, Xizhen Xu, Dao Wen Wang	35
14	P2y12 Receptor Promotes Pressure Overload–Induced Cardiac Remodeling via Platelet-Driven Inflammation in Mice 2017 ·Hypertension ·Lujin Wu, (unknown), (unknown), Huaping Li, Chen Chen, Jiali Nie, Peihua Wang, Dao Wen Wang	29
15	AMPKα2 Protects Against the Development of Heart Failure by Enhancing Mitophagy via PINK1 Phosphorylation 2017 ·Circulation Research ·Bei Wang, Jiali Nie, Lujin Wu, Yangyang Hu, Wen Zheng, Lingli Dong, Minghui Zou, Chen Chen, Dao Wen Wang	257
16	Sphingosine-1-phosphate ameliorates the cardiac hypertrophic response through inhibiting the activity of histone deacetylase-2 2017 ·International Journal of Molecular Medicine ·Hui Yan, (unknown), (unknown), Lujin Wu, Dao Wen Wang, Jiangang Jiang	18
17	Epoxyeicosatrienoic Acids Regulate Macrophage Polarization and Prevent LPS‐Induced Cardiac Dysfunction 2015 ·Journal of Cellular Physiology ·(unknown), Lujin Wu, (unknown), Shasha Zhang, Chen Chen, Xizhen Xu, Peihua Wang, Artiom Gruzdev, Darryl C. Zeldin, Dao Wen Wang	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact